1
|
Wehbe Z, Wehbe M, Iratni R, Pintus G, Zaraket H, Yassine HM, Eid AH. Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities. Front Immunol 2021; 12:663586. [PMID: 33859652 PMCID: PMC8043070 DOI: 10.3389/fimmu.2021.663586] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Accepted: 03/15/2021] [Indexed: 12/15/2022] Open
Abstract
As of January 2021, SARS-CoV-2 has killed over 2 million individuals across the world. As such, there is an urgent need for vaccines and therapeutics to reduce the burden of COVID-19. Several vaccines, including mRNA, vector-based vaccines, and inactivated vaccines, have been approved for emergency use in various countries. However, the slow roll-out of vaccines and insufficient global supply remains a challenge to turn the tide of the pandemic. Moreover, vaccines are important tools for preventing the disease but therapeutic tools to treat patients are also needed. As such, since the beginning of the pandemic, repurposed FDA-approved drugs have been sought as potential therapeutic options for COVID-19 due to their known safety profiles and potential anti-viral effects. One of these drugs is ivermectin (IVM), an antiparasitic drug created in the 1970s. IVM later exerted antiviral activity against various viruses including SARS-CoV-2. In this review, we delineate the story of how this antiparasitic drug was eventually identified as a potential treatment option for COVID-19. We review SARS-CoV-2 lifecycle, the role of the nucleocapsid protein, the turning points in past research that provided initial 'hints' for IVM's antiviral activity and its molecular mechanism of action- and finally, we culminate with the current clinical findings.
Collapse
Affiliation(s)
- Zena Wehbe
- Department of Biology, Faculty of Arts and Sciences, American University of Beirut, Beirut, Lebanon
| | - Maya Wehbe
- Department of Internal Medicine, Basingstoke & North Hampshire Hospital, Basingstoke, United Kingdom
| | - Rabah Iratni
- Department of Biology, College of Science, United Arab Emirates University, Al-Ain, United Arab Emirates
| | - Gianfranco Pintus
- Department of Medical Laboratory Sciences, College of Health Sciences, and Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates
- Department of Biomedical Sciences, University of Sassari, Sassari, Italy
| | - Hassan Zaraket
- Department of Experimental Pathology, Immunology and Microbiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
- Center for Infectious Disease Research (CIDR), Faculty of Medicine, American University of Beirut, Beirut, Lebanon
| | - Hadi M. Yassine
- Biomedical Research Center, Q.U. Health, Qatar University, Doha, Qatar
| | - Ali H. Eid
- Department of Basic Medical Sciences, College of Medicine, Q.U. Health. Qatar University, Doha, Qatar
- Biomedical and Pharmaceutical Research Unit, Q.U. Health, Qatar University, Doha, Qatar
| |
Collapse
|
2
|
Abstract
The macrocyclic lactone endectocides such as ivermectin, abamectin, selamectin and moxidectin have revolutionized the treatment of parasitic diseases in animals, being active against internal and external parasites. Ivermectin was introduced into veterinary medicine in the 1980s and since that time a number of related compounds have been introduced. In the treatment of internal parasites they complement the use of levamisole and the benzimidazoles, but in recent years they have found utility in treating external insect parasites. These agents show very low levels of toxicity under most circumstances. However, they are neurotoxic particularly in subpopulations of animals with mutations in the MDR1 gene. Toxicity may be also seen during off-label use, possibly because the doses used have been extrapolated from use in other animals. Regardless of these considerations, the macrocyclic lactone endectocides are extremely effective and safe drugs in the treatment of parasitic diseases of animals.
Collapse
Affiliation(s)
- K N Woodward
- TSGE, Concordia House, St James Business Park, Grimbald Crag Court Knaresborough, North Yorkshire UK.
| |
Collapse
|
3
|
Tisch DJ, Alexander NDE, Kiniboro B, Dagoro H, Siba PM, Bockarie MJ, Alpers MP, Kazura JW. Reduction in acute filariasis morbidity during a mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea. PLoS Negl Trop Dis 2011; 5:e1241. [PMID: 21765964 PMCID: PMC3134431 DOI: 10.1371/journal.pntd.0001241] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2010] [Accepted: 06/02/2011] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Acute painful swelling of the extremities and scrotum are debilitating clinical manifestations of Wuchereria bancrofti infection. The ongoing global program to eliminate filariasis using mass drug administration is expected to decrease this and other forms of filarial morbidity in the future by preventing establishment of new infections as a consequence of eliminating transmission by the mosquito vector. We examined whether mass treatment with anti-filarial drugs has a more immediate health benefit by monitoring acute filariasis morbidity in Papua New Guinean communities that participated in a 5-year mass drug administration trial. METHODOLOGY/PRINCIPAL FINDINGS Weekly active surveillance for acute filariasis morbidity defined by painful swelling of the extremities, scrotum and breast was performed 1 year before and each year after 4 annual mass administrations of anti-filarial drugs (16,480 person-years of observation). Acute morbidity events lasted <3 weeks in 92% of affected individuals and primarily involved the leg (74-79% of all annual events). The incidence for all communities considered together decreased from 0.39 per person-year in the pre-treatment year to 0.31, 0.15, 0.19 and 0.20 after each of 4 annual treatments (p<0.0001). Residents of communities with high pre-treatment transmission intensities (224-742 infective bites/person/year) experienced a greater reduction in acute morbidity (0.62 episodes per person-year pre-treatment vs. 0.30 in the 4(th) post-treatment year) than residents of communities with moderate pre-treatment transmission intensities (24-167 infective bites/person/year; 0.28 episodes per person-year pre-treatment vs. 0.16 in the 4(th) post-treatment year). CONCLUSIONS Mass administration of anti-filarial drugs results in immediate health benefit by decreasing the incidence of acute attacks of leg and arm swelling in people with pre-existing infection. Reduction in acute filariasis morbidity parallels decreased transmission intensity, suggesting that continuing exposure to infective mosquitoes is involved in the pathogenesis of acute filariasis morbidity.
Collapse
Affiliation(s)
- Daniel J. Tisch
- Case Western Reserve University, Cleveland, Ohio, United States of America
| | - Neal D. E. Alexander
- Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Benson Kiniboro
- Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
| | - Henry Dagoro
- Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
| | - Peter M. Siba
- Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
| | - Moses J. Bockarie
- Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
- Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Michael P. Alpers
- Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
- Curtin University, Perth, Australia
| | - James W. Kazura
- Case Western Reserve University, Cleveland, Ohio, United States of America
- * E-mail:
| |
Collapse
|
4
|
Abstract
OBJECTIVE To review the use of the oral antiparasitic ivermectin in the treatment of scabies, with an emphasis on its use in the elderly and in long-term care settings. DATA SOURCE A MEDLINE/PUBMED search was conducted to identify pertinent studies, case reports, letters, and reviews in the English language. All articles published from 1980 to October 2003 were reviewed. Additional references were obtained from the bibliographies of these articles. STUDY SELECTION All studies evaluating ivermectin in the context of scabies mite infestation. DATA SYNTHESIS The semisynthetic macrocyclic lactone ivermectin has been available since the early 1980s as a broad-spectrum antiparasitic agent in animals and humans. This agent, which works by suppressing motor nerve conduction leading to parasite paralysis and death, was first used in ectoparasitic diseases (i.e., those caused by lice and mites) shortly after commercial introduction. A large body of literature, mainly uncontrolled case reports and series, has since evolved. However, these reports and results of the small number of placebo- and/or active-controlled studies have demonstrated the favorable response of both classic and crusted scabies to single- and multiple-dose oral ivermectin. Adverse reactions to the drug are uncommon, with the exception of a transient, new onset, or mild increase in existing pruritus soon after drug ingestion, which is thought to be a hypersensitivity reaction to dead mites and/or their products. CONCLUSION Oral ivermectin may prove to be a time- and labor-saving alternative to topical scabicide treatments, especially in the institutional setting where labor shortages make the management of scabies outbreaks a true challenge. However, the use of this agent does not change the need to decontaminate the environment (clothing, bedding, bed clothes, and, in selected cases, floors and walls) in order to truncate an outbreak and prevent reinfestation.
Collapse
Affiliation(s)
- David R P Guay
- University of Minnesota College of Pharmacy, Minneapolis, MN 55455, USA.
| |
Collapse
|
5
|
Sparsa A, Bonnetblanc JM, Peyrot I, Loustaud-Ratti V, Vidal E, Bédane C. [Systemic adverse reactions with ivermectin treatment of scabies]. Ann Dermatol Venereol 2007; 133:784-7. [PMID: 17072195 DOI: 10.1016/s0151-9638(06)71044-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND Scabies is a common parasitic infestation and is very difficult to eradicate from institutions. Ivermectin is used extensively thanks to its efficacy and ease of use through oral administration; it was approved for the treatment of scabies in humans in 2001 in France. Most of the adverse effects noted with this drug have been seen during treatment of onchocerciasis and other filarial disease, but they are rare in the treatment of scabies. We report side effects with ivermectin in two elderly patients with scabies. CASES REPORT A 72-year-old man was referred for scabies and was treated with benzyl benzoate (Ascabiol) and ivermectin (200 microg/kg) in a single dose. Two days later, the patient presented abdominal pain and nausea. Laboratory tests revealed cytolysis tests for other causes of hepatitis were negative. Within two weeks, liver function had returned to normal. Hepatitis due to ivermectin was diagnosed. An 86-year-old woman hospitalised for scabies was treated with benzyl benzoate and a single dose of ivermectin (200 microg/kg). She developed sinus tachycardia and asthma 3 days later. Screening for embolic, cardiac and infectious origins was found. Toxicity of ivermectin was suspected. DISCUSSION Since the introduction of ivermectin for the treatment of scabies, reports of adverse events are rare although this drug can cause cardiac dysfunction and liver disease in other indications. In our cases, the causal relationship with ivermectin is probable and care must be taken, particularly in the elderly, the population in which this drug is probably most widely prescribed.
Collapse
Affiliation(s)
- A Sparsa
- Service de Dermatologie, CHU Dupuytren, 2, avenue Martin-Luther-King, 87042 Limoges Cedex.
| | | | | | | | | | | |
Collapse
|
6
|
Abstract
Scabies is a neglected parasitic disease that is a major public health problem in many resource-poor regions. It causes substantial morbidity from secondary infections and post-infective complications such as acute post-streptococcal glomerulonephritis. Disease control requires treatment of the affected individual and all people they have been in contact with, but is often hampered by inappropriate or delayed diagnosis, poor treatment compliance, and improper use of topical compounds such as permethrin, lindane, or benzyl benzoate. In addition to concerns over toxicity with such compounds, parasite resistance seems to be increasing. Oral ivermectin is an alternative that has been used successfully in community control programmes. Plant derivatives such as turmeric, neem, and tea tree oil are also promising future treatments. The disease is strongly associated with poverty and overcrowding, and the associated stigma can ostracise affected individuals. Treatment of scabies in poor countries needs to integrate drug treatment programmes with efforts to improve the socioeconomic conditions and education programmes to reduce stigma. We expect the future to bring more sensitive and specific clinical and laboratory-based diagnostic methods, as well as new therapeutic strategies.
Collapse
Affiliation(s)
- Jörg Heukelbach
- Department of Community Health, School of Medicine, Federal University of Ceará, Brazil
| | | |
Collapse
|
7
|
Abstract
Ivermectin is a synthetic derivative of the antiparasitic class of compounds known as avermectins. It is a macrolide endectocide with activity against both endoparasites with cutaneous tropism (Strongyloides stercoralis, Ancylostoma braziliense, Cochliomyia hominivorax, Dermatobia hominis, Filaria bancrofti, Wucheria malayi, Onchocerca volvulus, Loa-loa) and ectoparasites such as Sarcoptes scabies, Pediculus humanus, Demodex folliculorum, and Cheyletiella sp. Ivermectin is of great interest in the treatment of patients with different forms of scabies, head lice, demodecidosis, cutaneous larva migrans, cutaneous larva currens, myiasis, and filariasis.
Collapse
Affiliation(s)
- Assen L Dourmishev
- Department of Dermatology and Venereology, Medical University, Sofia, Bulgaria.
| | | | | |
Collapse
|
8
|
Abstract
Ivermectin is a potent antiparasitic drug and the first commercially available member of a new class of drugs (macrocyclic lactones) that has been approved for human use. Ivermectin has already proven to be highly effective in the elimination of river blindness as a public health burden. Side effects have been minor, and patient acceptance is good. Promising results in off-label applications for ectoparasitic infestations are increasingly important as resistance to topical therapy becomes more prevalent Ivermectin represents an advance in the therapeutic armamentarium and should be considered in appropriate cases.
Collapse
Affiliation(s)
- George W Elgart
- Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, 1444 North West 9th Avenue, Miami, FL 33136, USA.
| | | |
Collapse
|
9
|
Abstract
The standard treatment for scabies has long been based on topical scabicides. Ivermectin, a broad-spectrum anti-parasitic agent, was first used in veterinary medicine. This drug, active against nematodes and arthropods, is used in humans for the treatment of filariasis. For the past few years worldwide reports on the use of ivermectin in human scabies have suggested that this drug could be an alternative oral therapy.
Collapse
Affiliation(s)
- Pascal del Giudice
- Department of Infectious Diseases and Dermatology, Bonnet Hospital, Fréjus, France.
| |
Collapse
|
10
|
Abstract
INTRODUCTION Ivermectin is a semi-synthetic derivative of a family of macrocyclic lactones. This drug has a broad-spectrum anti-parasitic effect against various nematodes and ectoparasites. CURRENT KNOWLEDGE AND KEY-POINTS: Onchocerciasis and lymphatic filariasis are common indications. More recently ivermectin has been recommended in the treatment of strongyloidiasis and scabies. FUTURE PROSPECTS AND PROJECTS Promising results have been shown in the treatment of ascariasis, cutaneous larva migrans, loiasis and head lice.
Collapse
Affiliation(s)
- E Caumes
- Département des maladies infectieuses, tropicales et de parasitologie-mycologie, hôpital de la Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Paris, France
| | | |
Collapse
|
11
|
Affiliation(s)
- S Gibbs
- Department of Dermatology, Addenbrooke's NHS Trust, Cambridge, UK.
| |
Collapse
|
12
|
Chijioke CP. Factors affecting adverse event reporting during mass ivermectin treatment for onchocerciasis. Acta Trop 2000; 76:169-73. [PMID: 10936576 DOI: 10.1016/s0001-706x(00)00074-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
This study examines the effect of age, sex, dosing round, time of day, and distance from the nurse monitor on adverse event reporting during mass ivermectin administration at Achi, south-east Nigeria. There was a significant increase in adverse event reporting with age but no significant difference between the sexes. Both compliance and the incidence of reported adverse events were less during the second dosing round than during the first. Only three (2%) out of 144 subjects interviewed gave adverse events as a reason for non-compliance. Significantly fewer adverse events were reported as starting at night (22:00-06:00 h) than by day. The effect of distance on adverse event reporting was not statistically significant for distances up to 1 km.
Collapse
Affiliation(s)
- C P Chijioke
- Department of Pharmacology and Therapeutics, University of Nigeria Teaching Hospital, Enugu State, Nigeria.
| |
Collapse
|
13
|
Dunyo SK, Nkrumah FK, Simonsen PE. Single-dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Trans R Soc Trop Med Hyg 2000; 94:437-43. [PMID: 11127253 DOI: 10.1016/s0035-9203(00)90135-4] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Abstract
The effect of single-dose ivermectin (150-200 micrograms/kg) and albendazole (400 mg) treatment alone and in combination on Wuchereria bancrofti microfilaraemia, antigenaemia and clinical manifestations was compared 12 months after treatment in a double-blind placebo-controlled field trial carried out in Ghana in 1996-98, to evaluate the potential of these treatments for control. Both ivermectin and combination treatments resulted in pronounced reductions in microfilaraemia among individuals who were microfilaria positive before treatment. Among individuals who were positive for circulating filarial antigen before treatment, antigen levels increased considerably over the 1-year period after treatment in the placebo group, whereas they decreased in the ivermectin and combination groups. However, the post-treatment difference reached statistical significance in neither microfilaraemia nor antigenaemia between the ivermectin and the combination groups. Albendazole treatment alone showed only a minor effect on microfilaraemia and antigenaemia. No effect of the treatments on the incidence of new cases of microfilaraemia or antigenaemia, or on clinical manifestations, was observed. Both ivermectin and combination treatment thus appeared effective for control of W. bancrofti infections, but the difference in efficacy between the 2 treatments after 12 months appeared to be minimal.
Collapse
Affiliation(s)
- S K Dunyo
- Noguchi Memorial Institute for Medical Research, University of Ghana, P.O. Box 25, Legon, Ghana
| | | | | |
Collapse
|
14
|
Alberici F, Pagani L, Ratti G, Viale P. Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies. Br J Dermatol 2000; 142:969-72. [PMID: 10809857 DOI: 10.1046/j.1365-2133.2000.03480.x] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
In order to establish a safe and reliable treatment for human immunodeficiency virus (HIV)-associated scabies, we have treated 60 episodes of scabies in this setting, occurring in 39 patients, with one of the following regimens: (i) topical treatment with benzyl benzoate solution; (ii) single-dose oral treatment with ivermectin alone; and (iii) combination therapy with benzyl benzoate solution and oral ivermectin, employing the same regimens as single-agent therapy. Patients were stratified according to the severity score of the disease and the outcome (eradication, relapse, failure). We found that both benzyl benzoate and ivermectin alone were quite effective in mild to moderate scabies, but they were both associated with an unacceptable rate of relapse and failure in severe or crusted scabies. In contrast, combined treatment produced an optimal rate of success, without significant treatment-related side-effects. Therefore, we consider that combination treatment with benzyl benzoate solution and oral ivermectin is preferable to single-agent therapy in crusted scabies occurring in HIV/acquired immune deficiency syndrome patients.
Collapse
Affiliation(s)
- F Alberici
- Unit of Infectious Diseases, Azienda Ospedaliera di Piacenza, Via Taverna 49, I-29100 Piacenza, Italy
| | | | | | | |
Collapse
|
15
|
Bockarie MJ, Alexander ND, Kazura JW, Bockarie F, Griffin L, Alpers MP. Treatment with ivermectin reduces the high prevalence of scabies in a village in Papua New Guinea. Acta Trop 2000; 75:127-30. [PMID: 10708015 DOI: 10.1016/s0001-706x(99)00087-x] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- M J Bockarie
- Division of Geographic Medicine, Case Western Reserve University School of Medicine and University Hospital of Cleveland, OH 44106, USA.
| | | | | | | | | | | |
Collapse
|
16
|
|